SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: August 1, 2002
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Amarin Corporation plc appoints Bill Mason as director.
This report on Form 6-K is hereby incorporated
by reference in the registration statement on Form F-3
(Registration Statement No. 333-12642) of Amarin
Corporation plc and in the prospectus contained therein,
and in the Registration Statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc
and in the prospectus contained therein, and this report
on Form 6-K shall be deemed a part of each such
registration statement from the date on which this
report is filed, to the extent not superseded by
documents or reports subsequently filed.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: August 1, 2002
Index to
Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Amarin Corporation plc appoints
Bill Mason as Director.
Exhibit
(a)
Contacts:
Rick Stewart Mike Coffee
Chief Executive Officer President and Chief Operating Officer
Amarin Corporation plc Amarin Corporation plc
Phone: +44 (0) 207 907 2440 Phone: 415 389 4755
Email: rick.stewart@amarincorp.com Email: mike.coffee@amarinpharma.com
AMARIN CORPORATION PLC APPOINTS BILL MASON AS DIRECTOR
LONDON, United Kingdom, August 1, 2002 -- Amarin Corporation plc
(NASDAQ: AMRN) today announced the appointment of Dr Bill Mason as a
non-executive director, effective immediately. Dr Mason will also
serve as a member of the Company's audit committee.
Dr Mason is an entrepreneur with a strong scientific background in
healthcare and life sciences. He received his doctorate in
physiology from Trinity College, Cambridge in the UK in 1977. For
twenty years Dr Mason led a public- and industry-funded programme of
neuroscience-focused medical research using cellular and molecular
genetics, advanced computing and engineering technology for the
visualisation of chemical events in biological cells and high
throughput drug discovery. Much of this work was focused on
diagnostics and pharmaceuticals - as are his commercial activities
today. During this time, Dr Mason also played an active part as a
Member of ACOST (Advisory Council on Science and Technology) in the
UK Cabinet Office of HM Government focused on changes to the
educational system to effect the development of a more highly
qualified scientific and technical manpower base in Britain. He also
founded three successful high technology companies. Currently, Dr
Mason is Chairman of Cytomyx plc (AIM: CYX), Biotrin plc, Cytocell
and Team Consulting, a board director of Teraview and Acaris
Healthcare Solutions plc and an Advisory Board Member of Cambridge
Gateway Fund.
Amarin also announced the retirement of Mr Abhijeet Lele as a non-
executive director effective immediately. Mr Lele has served on
Amarin's board as an appointee of EGS Private Healthcare Partnership
following a private placement of a number of Amarin shares in June
2000.
"We are delighted with the appointment of Dr Mason to the board of
directors of Amarin" said Rick Stewart Amarin's CEO. "Dr Mason is a
highly experienced entrepreneur with a very strong scientific
background. His appointments to both the board and the Audit
Committee will I am sure add a further strong independent voice to
proceedings which can only be of benefit to both Amarin and its
investors. I would also like to take this opportunity to express
Amarin's appreciation for the contribution Abhijeet Lele has made to
the growth and success of Amarin to date."
Amarin Corporation plc is a specialty pharmaceutical company focused
on neurology and pain management. The Company plans to become a
leader in these therapeutic categories by providing innovative
products and solutions that address significant unmet medical needs.
For press releases and other corporate information, visit our
website at http://www.amarincorp.com.
Statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties
which may cause the Company's actual results in future periods to be
materially different from any performance suggested herein. Such
risks and uncertainties include, without limitation, risks
associated with the inherent uncertainty of pharmaceutical research,
product development and commercialisation, the impact of competitive
products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports. For more
information, please refer to Amarin Corporation's Annual Report for
2001 on Form 20-F and its Form 6-Ks as filed with the U.S.
Securities and Exchange Commission. The Company assumes no
obligation to update information on its expectations.